Loading...

Sequana Medical

ENXTBR:SEQUA
Snowflake Description

Limited growth with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SEQUA
ENXTBR
€103M
Market Cap
  1. Home
  2. BE
  3. Healthcare
Company description

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. The last earnings update was 88 days ago. More info.


Add to Portfolio Compare Print
SEQUA Share Price and Events
7 Day Returns
1.3%
ENXTBR:SEQUA
0.4%
Europe Medical Equipment
2.7%
BE Market
1 Year Returns
-
ENXTBR:SEQUA
4.6%
Europe Medical Equipment
-5.8%
BE Market
SEQUA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sequana Medical (SEQUA) 1.3% 0.9% -1.8% - - -
Europe Medical Equipment 0.4% -0.2% 6.3% 4.6% 59.7% 91.9%
BE Market 2.7% 3.6% -0.9% -5.8% -10.7% 8.8%
1 Year Return vs Industry and Market
  • No trading data on SEQUA.
  • No trading data on SEQUA.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Sequana Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Sequana Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sequana Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sequana Medical. This is due to cash flow or dividend data being unavailable. The share price is €6.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sequana Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sequana Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTBR:SEQUA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.40
ENXTBR:SEQUA Share Price ** ENXTBR (2019-07-19) in EUR €6.48
Europe Medical Equipment Industry PE Ratio Median Figure of 59 Publicly-Listed Medical Equipment Companies 31.98x
Belgium Market PE Ratio Median Figure of 87 Publicly-Listed Companies 14.99x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sequana Medical.

ENXTBR:SEQUA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:SEQUA Share Price ÷ EPS (both in EUR)

= 6.48 ÷ -1.40

-4.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sequana Medical is loss making, we can't compare its value to the Europe Medical Equipment industry average.
  • Sequana Medical is loss making, we can't compare the value of its earnings to the Belgium market.
Price based on expected Growth
Does Sequana Medical's expected growth come at a high price?
Raw Data
ENXTBR:SEQUA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
18.5%per year
Europe Medical Equipment Industry PEG Ratio Median Figure of 41 Publicly-Listed Medical Equipment Companies 2.42x
Belgium Market PEG Ratio Median Figure of 40 Publicly-Listed Companies 1.83x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sequana Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sequana Medical's assets?
Raw Data
ENXTBR:SEQUA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €-5.87
ENXTBR:SEQUA Share Price * ENXTBR (2019-07-19) in EUR €6.48
Europe Medical Equipment Industry PB Ratio Median Figure of 139 Publicly-Listed Medical Equipment Companies 3.28x
Belgium Market PB Ratio Median Figure of 119 Publicly-Listed Companies 1.55x
ENXTBR:SEQUA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:SEQUA Share Price ÷ Book Value per Share (both in EUR)

= 6.48 ÷ -5.87

-1.1x

* Primary Listing of Sequana Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sequana Medical has negative assets, we can't compare the value of its assets to the Europe Medical Equipment industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Sequana Medical's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Medical Equipment industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Sequana Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Sequana Medical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sequana Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sequana Medical expected to grow at an attractive rate?
  • Unable to compare Sequana Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Sequana Medical's earnings growth to the Belgium market average as it is expected to be loss making during the next 1-3 years.
  • Sequana Medical's revenue growth is expected to exceed the Belgium market average.
Annual Growth Rates Comparison
Raw Data
ENXTBR:SEQUA Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTBR:SEQUA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 18.5%
ENXTBR:SEQUA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 51%
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 18.1%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Belgium Market Earnings Growth Rate Market Cap Weighted Average 8%
Belgium Market Revenue Growth Rate Market Cap Weighted Average 3.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTBR:SEQUA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTBR:SEQUA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 35 1
2022-12-31 14 -4 -3 1
2021-12-31 6 -13 -12 2
2020-12-31 3 -11 -12 2
2019-12-31 2 -16 -13 1
ENXTBR:SEQUA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -10 -14
2018-09-30 1 -8 -10
2017-12-31 1 -8 -8
2016-12-31 1 -13 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sequana Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Sequana Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTBR:SEQUA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Sequana Medical Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTBR:SEQUA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 -0.20 -0.20 -0.20 1.00
2021-12-31 -0.94 -0.40 -1.47 2.00
2020-12-31 -0.92 -0.68 -1.16 2.00
2019-12-31 -1.00 -1.00 -1.00 1.00
ENXTBR:SEQUA Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.40
2018-09-30 -1.06
2017-12-31 -0.88
2016-12-31 -2.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sequana Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Sequana Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sequana Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sequana Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sequana Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sequana Medical does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Sequana Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sequana Medical's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Sequana Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sequana Medical Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTBR:SEQUA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.03 -13.98 9.16 1.81
2018-09-30 1.03 -10.42 9.18 1.15
2017-12-31 1.30 -8.23 7.51 1.00
2016-12-31 1.49 -13.97 13.99 1.15
2015-12-31 1.68 -11.56 11.95 0.99

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sequana Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Sequana Medical has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sequana Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Sequana Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sequana Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sequana Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sequana Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sequana Medical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Sequana Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sequana Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Sequana Medical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sequana Medical Company Filings, last reported 6 months ago.

ENXTBR:SEQUA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -18.76 14.65 1.32
2018-09-30 -13.35 10.92 0.54
2017-12-31 -4.61 4.58 1.68
2016-12-31 -6.67 4.66 0.80
2015-12-31 -0.28 0.00 1.43
  • Sequana Medical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Sequana Medical's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sequana Medical has less than a year of cash runway based on current free cash flow.
  • Sequana Medical has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.3% each year.
X
Financial health checks
We assess Sequana Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sequana Medical has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sequana Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sequana Medical dividends.
If you bought €2,000 of Sequana Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sequana Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sequana Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTBR:SEQUA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
Belgium Market Average Dividend Yield Market Cap Weighted Average of 77 Stocks 3.5%
Belgium Minimum Threshold Dividend Yield 10th Percentile 1.2%
Belgium Bottom 25% Dividend Yield 25th Percentile 2.3%
Belgium Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTBR:SEQUA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sequana Medical has not reported any payouts.
  • Unable to verify if Sequana Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sequana Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sequana Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sequana Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sequana Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sequana Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sequana Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ian Crosbie
CEO Bio

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December 22, 2016. He served as Chief Financial Officer of Sequana Medical AG from July 1, 2016 to December 22, 2016. He served as Chief Financial Officer at Global Consolidated Aesthetics Limited. Mr. Crosbie served as the Chief Financial Officer of GC Aesthetics PLC since January 2015 and served as its Principal Accounting Officer. He served as Senior Vice President of Corporate Development at Circassia Limited since 2013. Mr. Crosbie joined Circassia Limited on November 2013 and worked until December 2014. He has extensive senior-level strategic advisory experience in the life sciences industry. He served as Head of Healthcare Investment Banking at Jefferies Group LLC (formerly Jefferies Group, Inc.) since March 18, 2008. He served as a Managing Director in the healthcare investment banking group at Jefferies International Limited from March 2008 to April 2013. He served as Director of Healthcare Investment Banking at Deutsche Bank. He served as Managing Director at Ferghana Partners Group, a founder and Partner at Gargoyle Partners and a Director in the healthcare investment banking group at Deutsche Bank AG. He was founder of Gargoyle Partners in 2003 and joined FPG through the combination of the two firms in 2005. Together with Rawle Michelson, Mr. Crosbie was responsible for FPG’s activities in Europe across all product areas. He was Founder of Gargoyle Associates Ltd. and served as its Executive Officer. He was an Independent Corporate Consultant from May 2013 to October 2013. He is an experienced healthcare investment banker having worked for more than twelve years across all sectors of the industry, including pharmaceuticals, biotech, life sciences enabling tools, devices, diagnostics and services. He has a track record in M&A and equity & debt capital raising. Mr. Crosbie began his career with Bain & Co. as a Strategic Management Consultant both in London and California, before moving into investment banking with Baring Brothers in London. He then joined the healthcare team of Alex. Brown & Sons and was one of the original members of that team in Europe. Following the acquisition by Bankers Trust and Deutsche Bank. He served as co-head of Deutsche Bank’s European healthcare investment banking group, covering both financing and advisory products and all sectors of the industry. He served as an Equity Analyst of Deutsche Bank AG, Research Division. In 2003, Mr. Crosbie joined Rawle Michelson to found Gargoyle Partners and was a leading player in establishing the Rawle Michelson’s presence in the healthcare sector. He served as a Second Lieutenant in the 32ndArmoured Engineer Regiment of the British Army Mr. Crosbie received his MA (Oxon) in Engineering, Economics and Management from Oxford University.

CEO Compensation
  • Insufficient data for Ian to compare compensation growth.
  • Insufficient data for Ian to establish whether their remuneration is reasonable compared to companies of similar size in Belgium.
Management Team

Ian Crosbie

TITLE
CEO & Executive Director

Kirsten Van Bockstaele

TITLE
Chief Financial Officer
AGE
44

Lies Vanneste

TITLE
Director of Investor Relations
TENURE
0.3 yrs

Gijs Klarenbeek

TITLE
Chief Medical Officer
AGE
42

Martijn Blom

TITLE
Chief Commercial Officer
AGE
45
Board of Directors Tenure

Average tenure and age of the Sequana Medical board of directors in years:

0.4
Average Tenure
57
Average Age
  • The average tenure for the Sequana Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Pierre Chauvineau

TITLE
Chairman
AGE
55
TENURE
0.4 yrs

Ian Crosbie

TITLE
CEO & Executive Director
TENURE
0.4 yrs

Rudy DeKeyser

TITLE
Non-Executive Director
AGE
57

Erik Amble

TITLE
Non-Executive Director
AGE
67

Wim Ottevaere

TITLE
Independent Non-Executive Director
AGE
63
TENURE
0.4 yrs

Jason Hannon

TITLE
Independent Non-Executive Director
AGE
47
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sequana Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sequana Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. Its products include alfapump, a treatment solution for the long-term management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Details
Name: Sequana Medical NV
SEQUA
Exchange: ENXTBR
Founded: 2006
€102,689,817
15,847,194
Website: http://www.sequanamedical.com
Address: Sequana Medical NV
AA Tower,
Technologiepark 122,
Ghent,
East Flanders, 9052,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR SEQUA Ordinary Shares Euronext Brussels BE EUR 11. Feb 2019
BST 2SE Ordinary Shares Boerse-Stuttgart DE EUR 11. Feb 2019
Number of employees
Current staff
Staff numbers
34
Sequana Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/20 23:11
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/06/05
Last earnings filing: 2019/04/23
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.